About BioNexus Gene Lab Corp - Common stock (BGLC)
Bionexus Gene Lab Corp is a biotechnology company focused on the development and commercialization of innovative genomic solutions and technologies. The company specializes in harnessing the power of genetic research to create advanced diagnostic tools and therapeutic products aimed at improving health outcomes. Through its cutting-edge platforms, Bionexus aims to enhance our understanding of genetic diseases and facilitate precision medicine, thereby contributing to more effective treatments and personalized healthcare solutions. Read More
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
KUALA LUMPUR, Malaysia, March 08, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC’s Ethereum-based growth strategies. ML Tech is an AI-driven wealth management platform for digital assets regulated by the National Futures Association (NFA), and is headquartered in Miami, Florida. This collaboration follows the announced Ethereum treasury strategy by BGLC, marking its commitment to technological and financial innovation.
Medical technology company BioNexus Gene Lab Corp. (NASDAQ:BGLC) announced the adoption of Ethereum (CRYPTO: ETH) as a treasury reserve asset on Wednesday, following the cryptocurrency’s inclusion in th
KUALA LUMPUR, Malaysia, March 06, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC), a technology company dedicated to innovation in technology and healthcare, is pleased to announce that its Board of Directors has formally approved the Company’s new Ethereum-focused treasury strategy. This decision marks BGLC as the first Nasdaq-listed company to exclusively prioritize Ethereum (ETH) as a strategic treasury asset, and is in line with recent announcements of Ethereum being included in the US “Crypto Strategic Reserve”.
KUALA LUMPUR, Malaysia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- MRNA Scientific Sdn. Bhd. ("MRNA"), a subsidiary of BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), and Protech Builders Sdn. Bhd. ("Protech"), a leading mechanical and electrical engineering construction firm in Malaysia, are pleased to announce the signing of a strategic teaming agreement (the “Agreement”) to jointly develop and operate biogas plants across Malaysia. This collaboration marks a significant step in both companies' efforts to contribute to Malaysia's growing renewable energy sector, particularly in the generation of biogas from plantation wastewater.
KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce that its wholly owned subsidiary, MRNA Scientific Sdn. Bhd. (“MRNA Scientific”), has entered into a strategic outsourcing agreement with VITARRAY Global Pte. Ltd. (“Vitarray”), an exempted private company incorporated in Singapore. This agreement focuses on the provision of mRNA dynamic gene detection services for the Southeast Asian market.
